17th HIVHEP-PK presentations

  Other Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika
Dr. Steven Kern, Bill & Melinda Gates Foundation, USA
 Pharmacokinetics in infants and young children
  Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women
Dr. Minh Patrick Le, Hôpital Bichat-Claude Bernard, France
  Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection (IMPAACT P1110)
Dr. Diana Clarke, Boston Medical Center, USA
  Timing of the postpartum curve in pharmacokinetic studies in pregnancy should not be too early
Dr. Angela Colbers, Radboud Universitair Medisch Centrum, The Netherlands
 Hepatitis resistance and pharmacokinetics of DAAs
  Role of Resistance Testing
Dr. Shyam Kottilil, University of Maryland, USA
  The FDA Perspective on Hepatitis C Drug Resistance
Dr. Patrick Harrington, FDA, USA
  Effect of Renal Impairment on Drugs Primarily Eliminated by Metabolism or Biliary Excretion: Review of Data from HCV DAA Drugs and Literature
Dr. Tushar Garimella, Bristol-Myers Squibb, USA
  Effect of daclatasvir/asunaprevir/beclabuvir in fixed-dose combination on the pharmacokinetics of CYP450/transporter substrates in healthy subjects
Dr. Tushar Garimella, Bristol-Myers Squibb, USA
  Steady state ribavirin pharmacokinetics in chronic hepatitis C infected patients with moderate renal impairment taking modern DAA combinations: are we dosing too high?
Dr. Elise Smolders, Radboud Universitair Medisch Centrum, The Netherlands
  Evaluation of Drug-Drug Interaction Between Sofosbuvir/Velpatasvir and Rifaximin in HCV-Infected Subjects with Moderate Hepatic Impairment
Dr. Erik Mogalian, Gilead Sciences, USA
 Compartmental penetration of Antiretrovirals
  Cumulative tenofovir exposure is associated with decreased BMD in young and old HIV-infected adults on tenofovir based regimens
Dr. Sharon Seifert, University of Colorado Denver, USA
  Intracellular Metabolism of Tenofovir Alafenamide in Cervical and Vaginal Epithelial Cells
Dr. Mackenzie Cottrell, University of North Carolina, USA
  Pharmacogenetics of Efavirenz Discontinuation for Central Nervous System Symptoms at a Southeastern United States Clinic May Differ by Race
Dr. Paul Leger, Vanderbilt University Medical Center, USA
  Virologic and Immunologic Responses to Raltegravir and Dolutegravir in GALT of HIV+ Men and Women
Dr. Michael Weber, University of North Carolina at Chapel Hill, USA
 Long Acting Antivirals
  Target Concentrations
Dr. Angela Kashuba, UNC Eshelman School of Pharmacy, USA
  FDA Perspective on "oral run-in" phase
Dr. Yodit Belew, FDA, USA
  ViiV - Cabotegravir
Dr. Bill Spreen, ViiV, USA
  Janssen - Rilpivirine
Dr. Herta Crauwels, Janssen, Belgium
  Efficacy of once-weekly MK-8591 in SIV infected rhesus macaques
Dr. Matthew Rizk, Merck, USA
  In silico pharmacokinetic/pharmacodynamic simulation of long acting tenofovir injectable formulation for pre exposure prophylaxis strategies.
Dr. Paul Curley, University of Liverpool, United Kingdom
 Back to the Future: 40 years of Clinical Pharmacology
  Looking Backwards: Hormonal Contraception and ART 
Dr. Kim Scarsi, University of Nebraska, USA
  Pharmacogenetics - Back to reality
Dr. Andrew Owen, University of Liverpool, United Kingdom
  Will we see the Back of DDIs? 
Dr. Catia Marzolini, University Hospital Basel, Switzerland
  The ‘Back Side’ of Compartments
Dr. Saye Khoo, University of Liverpool, United Kingdom
  Back-terial co-infections
Dr. Mohammed Lamorde, Infectious Diseases Institute, Uganda
  Backing up clinical data with modelling 
Dr. Marco Siccardi, University of Liverpool, United Kingdom
 Clinical Guidance on how to interpret DDI’s
  Specific Complex Interactions (mechanic presentation)
Dr. David Burger, Radboudumc, The Netherlands
  Real life cases
Dr. Elise Smolders, Radboudumc, The Netherlands
 PK/PD of new and existing antivirals
  PBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine after Co-administration with Viekirax or Viekira Pak
Dr. Dwaipayan Mukherjee, AbbVie, USA
  Effects of Sofosbuvir/Ribavirin Treatment and ITPA Phenotype on Endogenous Purines
Dr. Leah Jimmerson, University of Colorado, USA
  Rifampin (RIF) Decreases Cabotegravir (CAB) Exposure following Oral Coadministration
Dr. Susan Ford, GlaxoSmithKline, USA
  Increased Tenofovir Diphosphate in Red Blood Cells, but Not Tenofovir in Plasma, with Sofosbuvir and Ribavirin
Dr. Christine MacBrayne, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, USA
  MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients
Dr. Nancy Kim, Merck & Co., USA
 Clinical Pharmacology Updates on New Compounds
  Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype (GT) 1 and Human Immunodeficiency Virus Type 1 (HIV-1)
Dr. Jennifer King, Abbvie, USA
  Physiologically-based simulation of daclatasvir pharmacokinetics with antiretroviral inducers and inhibitors of cytochrome P450 and drug transporters
Dr. Timothy Eley, Bristol-Myers Squibb, USA
  A Clinically Meaningful Drug-Drug Interaction Observed Between ZepatierTM (Grazoprevir/Elbasvir) and Stribild® HIV Fixed-Dose Combination in Healthy Subjects
Dr. Hwa-Ping Feng, Merck Sharpe & Dohme Corp., a subsidiary of Merck and Co., Inc., USA
  Pharmacokinetics of Dolutegravir after Switching to Abacavir/Dolutegravir/Lamivudine from an Efavirenz Based Regimen: A PK Substudy from Striiving
Dr. Jeff de Wet , ViiV Healthcare, USA
  Evaluation of Pan Genotypic HCV NS3/4A Protease Inhibitor GS-9857 as the Object of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions
Dr. Brian Kirby, Gilead Sciences, USA